BR112022004535A2 - Formulações de entrega de fármaco - Google Patents

Formulações de entrega de fármaco

Info

Publication number
BR112022004535A2
BR112022004535A2 BR112022004535A BR112022004535A BR112022004535A2 BR 112022004535 A2 BR112022004535 A2 BR 112022004535A2 BR 112022004535 A BR112022004535 A BR 112022004535A BR 112022004535 A BR112022004535 A BR 112022004535A BR 112022004535 A2 BR112022004535 A2 BR 112022004535A2
Authority
BR
Brazil
Prior art keywords
drug delivery
delivery formulations
risperidone
triblock
disorders
Prior art date
Application number
BR112022004535A
Other languages
English (en)
Portuguese (pt)
Inventor
Anthony Rech
Christophe Roberge
Eran Harary
Original Assignee
Medincell S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medincell S A filed Critical Medincell S A
Publication of BR112022004535A2 publication Critical patent/BR112022004535A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
BR112022004535A 2019-09-13 2020-09-11 Formulações de entrega de fármaco BR112022004535A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962900061P 2019-09-13 2019-09-13
PCT/IB2020/058474 WO2021048817A1 (en) 2019-09-13 2020-09-11 Drug delivery formulations

Publications (1)

Publication Number Publication Date
BR112022004535A2 true BR112022004535A2 (pt) 2022-06-07

Family

ID=72521677

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004535A BR112022004535A2 (pt) 2019-09-13 2020-09-11 Formulações de entrega de fármaco

Country Status (19)

Country Link
US (3) US12383493B2 (cg-RX-API-DMAC7.html)
EP (2) EP4706658A3 (cg-RX-API-DMAC7.html)
JP (2) JP7661312B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220062372A (cg-RX-API-DMAC7.html)
CN (1) CN114727946A (cg-RX-API-DMAC7.html)
AU (2) AU2020346455B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022004535A2 (cg-RX-API-DMAC7.html)
CA (1) CA3153793A1 (cg-RX-API-DMAC7.html)
DK (1) DK4027973T3 (cg-RX-API-DMAC7.html)
ES (1) ES3058225T3 (cg-RX-API-DMAC7.html)
FI (1) FI4027973T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251690T1 (cg-RX-API-DMAC7.html)
IL (1) IL291283A (cg-RX-API-DMAC7.html)
LT (1) LT4027973T (cg-RX-API-DMAC7.html)
MX (1) MX2022003051A (cg-RX-API-DMAC7.html)
PL (1) PL4027973T3 (cg-RX-API-DMAC7.html)
PT (1) PT4027973T (cg-RX-API-DMAC7.html)
SI (1) SI4027973T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021048817A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4027973T1 (sl) * 2019-09-13 2026-02-27 Medincell S.A. Formulacije za dostavo zdravil
US20240148641A1 (en) * 2021-03-17 2024-05-09 Medincell S.A. Long Acting Injectable Formulation Comprising Risperidone and Biodegradable Polymers
WO2026013080A1 (en) 2024-07-08 2026-01-15 InnoCore Technologies Holding B.V. Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007343A1 (en) * 1997-08-08 1999-02-18 University Of Utah Research Foundation Injectable biodegradable block copolymer gels for use in drug delivery
JP4223961B2 (ja) 2002-01-31 2009-02-12 Agcテクノグラス株式会社 霊長類胚性幹細胞の凍結保存方法
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
KR101707791B1 (ko) 2008-09-30 2017-02-17 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 리스페리돈 전달용 이식형 장치
CN101584652B (zh) * 2009-06-19 2012-06-20 上海医药集团股份有限公司 利培酮缓释凝胶注射剂及其制备方法
MY165655A (en) * 2010-12-29 2018-04-18 Medincell Biodegradable drug delivery compositions
WO2013063125A1 (en) * 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
KR102189442B1 (ko) * 2012-06-27 2020-12-11 메딘셀 에스.에이. 소수성 조성물용 생분해성 약물 전달
WO2014164754A1 (en) * 2013-03-11 2014-10-09 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
LT3655038T (lt) * 2017-07-17 2025-02-10 Medincell S.A. Farmacinė kompozicija
SI4027973T1 (sl) * 2019-09-13 2026-02-27 Medincell S.A. Formulacije za dostavo zdravil

Also Published As

Publication number Publication date
CA3153793A1 (en) 2021-03-18
AU2020346455A1 (en) 2022-03-31
JP2022548616A (ja) 2022-11-21
US20220331240A1 (en) 2022-10-20
JP7661312B2 (ja) 2025-04-14
MX2022003051A (es) 2022-06-14
HRP20251690T1 (hr) 2026-02-13
US12128132B2 (en) 2024-10-29
IL291283A (en) 2022-05-01
ES3058225T3 (en) 2026-03-09
US12383493B2 (en) 2025-08-12
EP4706658A2 (en) 2026-03-11
CN114727946A (zh) 2022-07-08
US20250268817A1 (en) 2025-08-28
DK4027973T3 (da) 2026-01-12
PT4027973T (pt) 2026-01-05
AU2020346455B2 (en) 2025-07-03
FI4027973T3 (fi) 2026-01-14
PL4027973T3 (pl) 2026-03-09
SI4027973T1 (sl) 2026-02-27
LT4027973T (lt) 2026-01-26
WO2021048817A1 (en) 2021-03-18
EP4706658A3 (en) 2026-06-03
EP4027973B1 (en) 2025-11-05
US20240156722A1 (en) 2024-05-16
EP4027973A1 (en) 2022-07-20
JP2025106353A (ja) 2025-07-15
AU2025242078A1 (en) 2025-10-23
EP4027973B8 (en) 2025-12-17
KR20220062372A (ko) 2022-05-16

Similar Documents

Publication Publication Date Title
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
BRPI0707235B8 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
MY199903A (en) Combination therapy with controlled-release cnp agonists
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
PT2526933E (pt) Inibidores da tirosina-quinase de bruton
BRPI0509863A (pt) liberação de fármaco para fundo de olho
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
WO2018111315A8 (en) PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES
EP4342532A3 (en) Antiplatelet drugs and uses thereof
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX387113B (es) Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor.
BR112021021826A8 (pt) Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4
MX2019006463A (es) Composiciones farmaceuticas que contienen insulina.
MX2022003051A (es) Formulaciones para la administracion de farmacos.
MX377897B (es) Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MY193963A (en) Composition for treating joint diseases and kit containing same

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122025009310-6 PROTOCOLO 870250037735 EM 09/05/2025 15:29.